S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Boston Scientific (BSX) Competitors

$67.33
-0.09 (-0.13%)
(As of 04/19/2024 ET)

BSX vs. SYK, BDX, DXCM, RMD, WST, CI, REGN, VRTX, BMY, and MDT

Should you be buying Boston Scientific stock or one of its competitors? The main competitors of Boston Scientific include Stryker (SYK), Becton, Dickinson and Company (BDX), DexCom (DXCM), ResMed (RMD), West Pharmaceutical Services (WST), The Cigna Group (CI), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), and Medtronic (MDT). These companies are all part of the "medical" sector.

Boston Scientific vs.

Boston Scientific (NYSE:BSX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking.

Stryker has a net margin of 15.44% compared to Boston Scientific's net margin of 11.19%. Stryker's return on equity of 22.99% beat Boston Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Boston Scientific11.19% 15.99% 8.87%
Stryker 15.44%22.99%10.69%

Stryker has higher revenue and earnings than Boston Scientific. Stryker is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Boston Scientific$14.24B6.94$1.59B$1.0762.93
Stryker$20.50B6.04$3.17B$8.2539.45

Boston Scientific has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Boston Scientific presently has a consensus target price of $68.50, suggesting a potential upside of 1.74%. Stryker has a consensus target price of $340.45, suggesting a potential upside of 4.62%. Given Stryker's higher possible upside, analysts clearly believe Stryker is more favorable than Boston Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific
0 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
1 Strong Buy rating(s)
3.00
Stryker
0 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.77

89.1% of Boston Scientific shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.5% of Boston Scientific shares are held by insiders. Comparatively, 5.9% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Boston Scientific had 10 more articles in the media than Stryker. MarketBeat recorded 25 mentions for Boston Scientific and 15 mentions for Stryker. Stryker's average media sentiment score of 0.85 beat Boston Scientific's score of 0.57 indicating that Stryker is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Boston Scientific
9 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Positive
Stryker
10 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Boston Scientific received 103 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.12% of users gave Boston Scientific an outperform vote while only 64.43% of users gave Stryker an outperform vote.

CompanyUnderperformOutperform
Boston ScientificOutperform Votes
985
69.12%
Underperform Votes
440
30.88%
StrykerOutperform Votes
882
64.43%
Underperform Votes
487
35.57%

Summary

Stryker beats Boston Scientific on 10 of the 19 factors compared between the two stocks.

Get Boston Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BSX vs. The Competition

MetricBoston ScientificSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$98.78B$3.69B$4.89B$17.26B
Dividend YieldN/A2.18%2.93%3.59%
P/E Ratio62.9311.24161.4621.17
Price / Sales6.9455.772,465.839.63
Price / Cash23.1943.1647.3117.28
Price / Book5.054.224.564.85
Net Income$1.59B$4.44M$104.37M$970.56M
7 Day Performance-1.09%-3.81%-4.52%-1.76%
1 Month Performance-0.33%-8.24%-6.80%-4.32%
1 Year Performance31.74%12.82%6.60%92.59%

Boston Scientific Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYK
Stryker
4.7851 of 5 stars
$337.54
-0.5%
$339.22
+0.5%
+7.7%$128.42B$20.50B40.9152,000
BDX
Becton, Dickinson and Company
4.7653 of 5 stars
$231.01
-1.6%
$280.00
+21.2%
-10.6%$66.74B$19.37B54.7473,000Short Interest ↑
News Coverage
DXCM
DexCom
4.3799 of 5 stars
$136.52
+1.5%
$141.40
+3.6%
+7.0%$52.63B$3.62B104.219,600Upcoming Earnings
Insider Selling
RMD
ResMed
4.8256 of 5 stars
$184.85
-0.1%
$199.20
+7.8%
-20.5%$27.19B$4.22B30.5510,140Upcoming Earnings
News Coverage
WST
West Pharmaceutical Services
4.7892 of 5 stars
$379.48
+0.2%
$435.20
+14.7%
+2.9%$27.78B$2.95B48.1610,600Upcoming Earnings
Analyst Revision
News Coverage
CI
The Cigna Group
4.8247 of 5 stars
$346.79
-0.6%
$362.14
+4.4%
+37.8%$101.39B$195.27B19.9472,500Positive News
REGN
Regeneron Pharmaceuticals
3.6692 of 5 stars
$894.14
-0.5%
$970.57
+8.5%
+12.4%$98.14B$13.12B25.7313,450Analyst Report
Gap Up
VRTX
Vertex Pharmaceuticals
4.3369 of 5 stars
$394.17
-0.8%
$424.62
+7.7%
+19.8%$101.88B$9.87B28.385,400Analyst Report
Analyst Revision
News Coverage
BMY
Bristol-Myers Squibb
4.8512 of 5 stars
$48.27
-0.5%
$61.12
+26.6%
-29.6%$97.83B$45.01B12.5134,100Upcoming Earnings
Analyst Report
Short Interest ↓
Analyst Revision
MDT
Medtronic
4.5884 of 5 stars
$79.25
-1.2%
$94.91
+19.8%
-4.8%$105.23B$31.23B25.2495,000

Related Companies and Tools

This page (NYSE:BSX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners